Highest-materiality recent filing
Ligand completes acquisition of XOMA Royalty for $39.00/share plus CVRs
Stockholders received $39.00 cash per share plus one CVR per share entitling holder to 75% of net proceeds from certain pending litigation.
XOMA redeems all preferred stock, sets CVR record date; merger closing on July 14
Redemption of all 984K Series A and 1.76M Series B depositary shares on July 14 at $25/sh plus accrued dividends.
XOMA Royalty stockholders approve equity plan amendments, new ESPP, and bylaw forum provision
Stockholders approved amendment to 2010 Long Term Incentive Plan, increasing share reserve by 425,000 and extending term to 2036.
XOMA Royalty amends merger agreement to add newly formed holding company for Ligand acquisition
HoldCo (XOMA Royalty Holdings Corporation) formed on May 15, 2026 and added as party to the Merger Agreement with Ligand Pharmaceuticals.
XOMA completes Generation Bio acquisition; estimates CVR value at $0.81/share
XOMA paid $4.2913 per share cash plus one non-tradeable CVR for Generation Bio; ~70% of shares tendered.
Ligand to acquire XOMA Royalty for $39.00/share cash plus contingent value rights
Per-share consideration: $39.00 cash plus CVRs representing rights to 75% of net proceeds from Janssen litigation.
XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY
Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.
Filed March 2, 2026: updated corporate presentation made available as Exhibit 99.1.
XOMA Royalty closes acquisition of Generation Bio for $4.2913/share plus CVR
Completed tender offer; 4,722,533 shares (approx. 70%) tendered, all accepted.
XOMA completes acquisition of LAVA legacy assets; details Pfizer, Janssen programs and CVR terms
XOMA completed acquisition of LAVA legacy assets (EGFRd2, JNJ-89853413, LAVA-1266) on Nov 20, 2025.
XOMA Royalty names Jeffrey Trigilio CFO; Thomas Burns departs after ~19 years
Thomas Burns stepped down as CFO effective Jan 12, 2026; separation agreement includes $16k/month consulting for 3 months.
XOMA Royalty posts updated corporate presentation; no specific material changes disclosed
Filed updated corporate presentation on Form 8-K dated January 12, 2026 (Exhibit 99.1).
XOMA Royalty completes acquisition of Mural Oncology for $2.035/share
Deal closed Dec 5, 2025; Mural shareholders received $2.035 cash per share.
XOMA completes acquisition of LAVA Therapeutics for $1.04/share plus CVRs
Subsequent Offering Period expired Nov 20, 2025; Post-Offer Reorganization effective same day.
XOMA Royalty Q3 net income $14.1M vs loss $17.2M; revenue $9.4M; cash receipts $43.9M YTD
Net income of $14.1M in Q3 2025, compared to net loss of $17.2M in Q3 2024.
XOMA enters ATM sales agreements for up to $125M in common stock and preferred depositary shares
Up to $75M common stock ATM with Leerink Partners; 3% commission.
XOMA corrects typo in Series B preferred stock certificate of designation
Certificate of Correction filed Sept 23, 2025 for Series B Cumulative Perpetual Preferred Stock.
XOMA completes acquisition of HilleVax for $1.95 per share plus CVR
XOMA acquired HilleVax via tender offer and merger; offer price of $1.95 cash plus one CVR per share.
XOMA completes acquisition of Turnstone Biologics for $0.34 cash plus CVR per share
XOMA accepted 17,192,002 shares (~74% of outstanding) at $0.34 plus one CVR per share.
XOMA Royalty Q2 net income $9.2M; acquires Turnstone, HilleVax, LAVA; H1 cash receipts $29.6M
Net income $9.2M (Q2 2025) vs $16.0M (Q2 2024); income & revenue $13.1M vs $11.1M.
XOMA stockholders approve reincorporation to Nevada and increase in equity plan shares by 880,000
Reincorporation from Delaware to Nevada effective May 30, 2025; no change in business, management, or assets.
Q1 2025 total revenues $15.9M (vs $1.5M Q1 2024); net income $2.4M (vs net loss $8.6M).
XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets
Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.
XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024
XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.
XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest
Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.
XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired
Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.
XOMA Royalty acquires 50% of Twist Bioscience's royalty/milestone economics for $15M
Acquired 50% economic interest in milestones/royalties from Twist's 60+ early-stage programs across 30 partners for $15M upfront.
FDA approves Zevra's MIPLYFFA for NPC; XOMA holds royalty on sales up to $52.6M milestones
FDA approved MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on Sept 20, 2024.
Net income $16.0M vs net loss $5.4M in Q2 2023; total income/revenue $11.1M; cash receipts $22.6M.
XOMA Corporation changing name to XOMA Royalty Corporation on July 10, 2024
Name change effective 12:01 a.m. ET on July 10, 2024; ticker 'XOMA' and CUSIP unchanged.
XOMA closes Kinnate acquisition for $122.7M cash; Q1 2024 pro forma net loss $21.7M
Cash consideration of $2.5879 per share + one CVR; aggregate cash $122.7M financed from cash on hand.
XOMA to receive $8.1M from Viracta after Day One sells PRV for $108M
Day One Biopharmaceuticals sold a priority review voucher for $108M after FDA approval of OJEMDA.
XOMA shareholders elect all seven director nominees and ratify Deloitte as auditor
All seven director nominees elected with >99% votes for (excluding broker non-votes).
XOMA Q1 net loss $8.6M; FDA approves OJEMDA triggering $9M milestone
Q1 revenue $1.5M (vs $0.4M YoY) on $1M AVEO milestone; net loss $8.6M (vs $9.8M YoY).
XOMA pays $22M upfront for royalty interests in three women's health assets from Daré Bioscience
XOMA paid $22M cash to Daré for royalties on XACIATO, Ovaprene, and Sildenafil Cream.
XOMA earns $9M milestone on FDA approval of Day One's OJEMDA for pediatric low-grade glioma
XOMA earned $9M milestone from FDA accelerated approval of Day One's OJEMDA (tovorafenib) for relapsed/refractory BRAF-altered pLGG.
XOMA completes acquisition of Kinnate Biopharma for $2.5879 per share plus CVRs
XOMA purchased ~81% of Kinnate shares via tender offer at $2.5879/share plus one CVR per share.
XOMA reports Q4 2023 net loss $20.1M, revenue $1.8M; cash $159.6M
Full year 2023 net loss $40.8M vs $17.1M in 2022; revenue $4.8M vs $6.0M.
XOMA to acquire Kinnate Biopharma for up to $2.5879 per share plus CVR
Cash consideration of $2.3352 base plus up to $0.2527 additional per share; plus CVR for 85% or 100% of program sale proceeds.
XOMA appoints Owen Hughes as permanent CEO, boosts salary to $575K; chairman changes
Owen Hughes, previously interim CEO, appointed CEO and director effective Jan 7, 2024; base salary raised to $575,000.
XOMA announces first stock repurchase program of up to $50M through January 2027
Board authorized repurchase of up to $50M of common stock through January 2027.
XOMA secures up to $140M non-dilutive royalty-backed loan from Blue Owl at 9.875%
XOMA draws $130M initial term loan; can draw additional $10M if VABYSMO royalties exceed threshold by March 2026.
XOMA reports Q3 net loss of $5.5M, highlights NDA filings and $5M milestone from Day One
Q3 revenues $0.8M vs $0.5M YoY; net loss $5.5M vs $4.2M YoY.
FDA accepted Day One Biopharmaceuticals' NDA for tovorafenib as monotherapy for relapsed/progressive pediatric low-grade glioma.
Organon terminates ebopiprant license agreement with XOMA; XOMA to seek new partner
Organon notified XOMA of intent to terminate License Agreement for ebopiprant; effective Jan 21, 2024.
XOMA receives $4.9M commercial payment from Genentech for VABYSMO H1 2023 sales
Received $4.9 million from Genentech (Roche) for VABYSMO net sales in first six months of 2023.
Novartis discontinues development of XOMA-licensed NIS793 anti-TGFß antibody
On Aug 25, 2023, Novartis notified XOMA it will stop development of NIS793 (anti-TGFß monoclonal antibody).
XOMA Q2 net loss $5.4M; revenue $1.7M, cash $31.4M; two royalty deals in H1
Total revenue $1.7M (Q2 2022: $1.0M), driven by $1.1M milestone from Janssen license.
Novartis stopped Phase 3 trial (NCT04935359) of NIS793 in first-line metastatic PDAC based on benefit-risk assessment.
XOMA acquires LadRx royalty/milestone rights for arimoclomol and aldoxorubicin for $5M upfront
Acquired 100% of LadRx's royalty and milestone rights for arimoclomol (NPC) and aldoxorubicin (ImmunityBio).
the directors of Merger Sub as of immediately prior to the Effective Time, Todd C. Davis, Octavio Espinoza and Andrew Reardon, became the directors of the Company
each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company
the directors of Merger Sub as of immediately prior to the Effective Time, Todd C. Davis, Octavio Espinoza and Andrew Reardon, became the directors of the Company
each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company
each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company
each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company
each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company
each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company
each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company
the directors of Merger Sub as of immediately prior to the Effective Time, Todd C. Davis, Octavio Espinoza and Andrew Reardon, became the directors of the Company
On January 7, 2024, the board of directors (the “Board”) of XOMA Corporation, a Delaware corporation (the “Company”), appointed Owen Hughes, previously Interim Chief Executive Officer, to serve as the Company’s Chief Executive Officer and to continue serving as principal executive officer and a director, effective immediately.
appointed Owen Hughes as our Interim Chief Executive Officer and principal executive officer and as a member of our Board and Executive Chairman of our Board, effective as of January 1, 2023.
Max materiality 1.00 · Median 0.68 · Most common event other_material